CAS 475085-57-5 appears in our catalog under these names: Selexipag Metabolite (MRE-269, ACT-333679), MRE-269, >95% (HPLC), MRE-269/ 99.57% (existing batch purity), MRE-269 98%, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid, 98%, 98%. Offered by: Chemat Brand, TRC, TargetMol, Ambeed, Chemat. Available pack sizes: on request, 50mg, 5mg, 10mg, 25mg, 100mg, 200mg, 1mg.
ACT-333679 is a member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as a vasodilator agent, a drug metabolite, a platelet aggregation inhibitor, an orphan drug and a prostacyclin receptor agonist. It is a monocarboxylic acid, an ether, an aromatic amine, a sulfonamide, a member of pyrazines and a tertiary amino compound.
Source: ChEBI
| Molecular formula | C25H29N3O3 |
|---|---|
| Molecular weight | 419.5 g/mol |
| IUPAC name | 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid |
| InChIKey | OJQMKCBWYCWFPU-UHFFFAOYSA-N |
| SMILES | CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3 |
Computed by PubChem (NCBI)